https://www.businesswire.com/news/home/20190411005474/en/

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr 11, 2019--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data on the use of its chronic hepatitis B (HBV) and hepatitis C (HCV) medicines including safety and efficacy data on Vemlidy ® (tenofovir alafenamide 25mg, TAF) in HBV patients previously treated with tenofovir disoproxil fumarate (TDF) and data on Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni ® (ledipasvir 90mg/sofosbuvir 400mg) in difficult-to-cure HCV patient populations. These results, along with data from Gilead’s HBV cure research program, will be presented at The International Liver Congress™ (ILC) 2019 in Vienna, Austria.

“As part of our ongoing commitment to patients living with viral hepatitis, we continue to research the roles of our HBV and HCV medicines across the broadest range of patient populations. These latest data demonstrate that the efficacy of our HCV medicines is consistent in clinical trials and in real-world settings, even in difficult-to-cure patients,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead Sciences. “In HBV, our latest research reinforces the role of Vemlidy in chronic HBV management and the importance of ongoing research in pursuit of an HBV cure.”